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Summary Background: An appropriate treatment of older lung cancer patients has become
an important issue. The aim of this study is to evaluate the short and long-term surgical out-
comes in lung cancer patients using 70 years as a cut-point, and to identify prognostic factors
of cancer-specific mortality in patients older than 70 years.
Methods: Medical records of non-small cell lung cancer (NSCLC) patients who underwent pul-
monary resection at Chiang Mai University Hospital from January 2002 through December 2016
were retrospectively reviewed. Patients were divided into age less than 70 years (control
group) and 70 years or more (study group). Primary outcomes were major post-operative com-
plications and in-hospital death (POM); secondary outcome was long-term survival.
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Multivariable regression analysis was used.
Results: This study included 583 patients, 167 for study group, and 416 for control group. There
were no differences in POM, both at univariable and multivariable analyses, however, for long-
term cancer-specific mortality, the study group was more likely to die (HRadj Z 1.40, 95%
CI Z 1.03e1.89). Adverse prognostic factors for long-term mortality in study group were hav-
ing universal coverage scheme (HRadj Z 1.70, 95%CI Z 1.03e2.79), the presence of intratu-
moral lymphatic invasion (HRadj Z 2.83, 95%CI Z 1.28e6.29), perineural invasion
(HRadj Z 2.80, 95%CI Z 1.13e6.94), underwent lymph node sampling (HRadj Z 2.23, 95%
CI Z 1.16e4.30) and higher stage of disease (HRadj Z 2.02, 95%CI Z 1.06e3.85 for stage III,
HRadj Z 3.40, 95%CI Z 1.29e8.94 for stage IV).
Conclusions: In-hospital mortality and composite post-operative complications are acceptable
in pulmonary resection for NSCLC patients older than 70 years. However, these patients had
shorter long-term survival, especially who have some adverse prognostic factors. Further
studies with larger sample size are warranted.
ª 2019 Asian Surgical Association and Taiwan Robotic Surgery Association. Publishing services
by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Surgical treatment is the standard of care with curative
intent in early stage non-small cell lung cancer (NSCLC)
patients, but also for symptomatic treatment in advanced
disease. Nowadays, because of increasing in life span, and
more than one-third of lung cancer patients being age >70
years old,1,2 defining the appropriate treatment of elderly
lung cancer patients has become an important issue in
terms of perioperative morbidity, mortality and overall
survival. Because of physiological changes in the cardio-
vascular and pulmonary function in elderly patients,
morbidity and mortality after pulmonary resection should
be a concern. Previous studies reported that there are
approximately 30e50% postoperative complications in
elderly NSCLC patients,3e5 therefore alternative treatment
strategies and surgical techniques were developed for
avoiding postoperative complications such as stereotactic
body radiotherapy, and minimally invasive approach.6e8
Although previous studies demonstrated excellent out-
comes with acceptable postoperative morbidity and mor-
tality in elderly patients after either sublobar resection or
lobectomy,2,9,10 some studies report worse short-term and
long-term outcomes in elderly patients (age70 years) in
comparison to younger ones.11 In this study, we retrospec-
tively reviewed data on NSCLC patients who underwent
curative pulmonary resection to analyze the short and long-
term surgical outcomes comparing between patients age
<70 years and age 70 years, to determine the impact of
age on long-term survival and to identify prognostic factors
of long-term cancer-specific mortality in patients age more
than 70 years.
2. Patients and methods
This is a retrospective cohort study. Medical records of non-
small cell lung cancer (NSCLC) patients who underwent
pulmonary resection (either curative or palliative intent)
with systematic mediastinal lymph node dissection or
sampling in the general thoracic surgery unit, department
of surgery, faculty of medicine, Chiang Mai university,
Chiang Mai, Thailand between January 2002 to June 2015
were retrospectively reviewed. Clinical characteristics
including age, gender, history of smoking, family history of
cancer, comorbidities, patient physical status, laboratory
findings, pre-operative cardiac and pulmonary function
testing, surgery information, pathologic report and post-
operative outcomes were extracted. The cut-of-point for
age is debatable, however, according to previous stud-
ies,12e15 we used the age of 70 years to divide all eligible
patients into two groups; study group (age  70 years) and
control group (age <70 years). The primary outcome was
composite: major postoperative complication (POM)
(including in-hospital mortality, pneumonia, acute respira-
tory distress syndrome (ARDS), intubation more than 24 h
after surgery (delayed extubation), re-intubation, trache-
ostomy, atelectasis needing bronchoscopy and prolonged
air leak more than 5 days according to STS GTDB guide-
lines.16 The secondary outcomes were length of hospital
stay, long-term cancer-specific mortality, and tumor
recurrence. This study was reviewed and approved by the
Institutional Review Board of Faculty of Medicine, Chiang
Mai University, Chiang Mai, Thailand with Study Code: SUR-
2558-033491/Research ID: 3349, and approval ID 434/2015.
All patients received preoperative cancer staging
including computed tomography (CT) with contrast or
whole-body positron emission tomography, bronchoscopy
with biopsy, bronchial washing, brushing or bronchial
lavage cytology. If mediastinal lymph nodes were larger
than 1 cm, endobronchial ultrasound-guided (EBUS) fine
needle aspiration, or mediastinoscope biopsy were per-
formed. All patients had a biochemistry profile, a pulmo-
nary function test, a room-air arterial blood gas, and an
electrocardiography.
The pulmonary resections included wedge, segmentec-
tomy, lobectomy and pneumonectomy, both for curative
intent or palliative resection. The indication for sublobar
resection (wedge resection or segmentectomy) included
patients who had maximum tumor size less than 2 cm and
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severe comorbid diseases or poor-pulmonary reserved
function according to American College of Chest Physicians
Evidence-Based Clinical Practice Guideline.17 Surgical ap-
proaches included open thoracotomy and video-assisted
thoracoscopic approach (VATS). Systematic mediastinal
lymph node dissection (SLND) or sampling (SLNS) were
performed in all cases. According to European Society of
Thoracic Surgeons guidelines, systematic mediastinal lymph
node dissection is to dissect and remove all mediastinal
tissue containing the lymph nodes within anatomic land-
mark at least three mediastinal nodal stations, including
the subcarinal node. Systematic mediastinal lymph node
sampling means a lesser excision of certain nodal stations
that seem to be representative or abnormal in preoperative
evaluations or intraoperative.18 Lymph node mapping was
issued by International Association for the Study of Lung
Cancer (IASLC), original by Naruke et al.19 Lymph node ratio
was calculated by the proportion of positive dissected
lymph node over the total number of dissected lymph node.
Tumor staging was reviewed according to the 8th edition of
the TNM classification for lung cancer issued by (IASLC).20
After discharge, patients were followed up at 2 weeks
and 1e2 months with CXR and physical examination, and
then every 3 months for the first two years and then every 6
months with CT-scan. When tumor recurrence was sus-
pected, diagnostic procedures were performed to confirm
the diagnosis either with cytology or diagnostic radiology.
Patients received chemotherapy and/or radiotherapy ac-
cording to their performance status and tumor status. The
regimens of chemotherapy included cisplatin, carboplatin,
vinorelbine, vinorelbine, gemcitabine, docetaxel, peme-
trexed and targeted therapy (erlotinib, gefitinib, crizotinib)
depending on molecular testing and insurance coverage.
Overall survival and recurrence-free survival were calcu-
lated from the date of surgery to the most recent follow-up
contact or to the date of death, and from the date of first
tumor diagnosis to either local recurrence or distant
metastasis, respectively.
2.1. Statistical analysis
categorical variables were presented as frequency and
proportion (%); continuous variables were presented as
mean  standard deviation (SD) or median  interquartile
range (IQR) depending on the data distribution. When the
two groups were compared, Fisher exact test was used for
categorical data and unpaired student t-test or Wilcoxon
rank sum test for continuous variables. Univariable and
multivariable logistic regression analysis were used to
identify risk factors of POM and presented with odd ratios
and 95% confidence intervals; matching propensity score
was also performed and showed in the supplement data.
Multiple imputations with multivariate normal equation
were performed for any variables with at least 10% missing
values.21 We then compared the results from a complete-
case analysis with the results of multiple imputations (MI)
analysis. Cox proportional hazard model was used to assess
prognostic factors of recurrence of disease and long-term
survival, which were presented as hazard ratios with 95%
confidence interval. Any risk factors or prognostic factors
with p value < 0.1 in the univariable analyses and other
potential clinical confounders associated with POM, tumor
recurrence, and long-term survival were included in the
multivariable analysis model. Multicollinearity of indepen-
dent factors was tested before performing multivariable
analysis. Patients with stage IV disease were excluded when
analyzing for prognostic factors for tumor recurrence. The
statistical analysis was completed in STATA statistical
package (Release 15.1,2018; StataCorp, CS, TX, USA), with
p < 0.05 indicating a statistically significant difference.
3. Results
There were 583 patients diagnosed with NSCLC who under-
went curative or palliative pulmonary resection enrolled in
this study, 167 in study group and 416 in control group. The
mean age was 62.4  10.4 years (range from 18 to 86 years),
74.5  4.0 years in the study group and 57.5  8.0 years in
the control group. Their demographics, preoperative char-
acteristics, and pathologic results are shown in Table 1.
There were 36 patients diagnosed stage IVA who underwent
pulmonary resection; 20 patients presented with single brain
metastasis and received whole brain radiation or excision
and 16 patients had single lung to lung metastasis. Patients
in the study group were more likely to have the civil servant
medical benefit scheme, be active smoker, have a higher
number of pack-year of smoking, COPD, HT, dyslipidemia,
abnormal preoperative ECG than patients in the control
group. There were no statistically significant differences in
gender, body mass index, preoperative pulmonary function
test, ejection fraction, tumor stage and pathologic findings
between the two groups. Patients in the study group were
more likely to undergo sublobar resection (wedge resection
or segmentectomy), SLNS, and to die in hospital, whereas
less likely to receive chemotherapy (either adjuvant or
neoadjuvant regimen), and to be immediately extubated
after surgery than those in the control group (Table 2). There
were no statistically significant differences in term of
approach (VATS or open thoracotomy), lymph node ratio,
operative time, estimated blood loss, and length of intensive
care unit stay between the two groups. Postoperative com-
plications, major complications, and overall mortality were
not different between the two groups. However, in-hospital
mortality, postoperative arrythmia, air leak, acute renal
failure and other minor complications were documented
more often among patients in the study group than the
control group. The most common postoperative complica-
tion in both groups was postoperative air leak; these patients
only had forced expiratory air leak and success for conser-
vative treatment. The incidence of postoperative acute
renal failure in the study group was higher than in the con-
trol group (2.5% versus 0.5%, p Z 0.059). Patients in the
study group had shorter follow-up time than the control
group. In a subgroup analysis according to stage, patients in
the study group were more likely to undergo sublobar
resection than those in the control group; however, only
stage IA3 patients showed a statistically significant differ-
ence between the two groups (Supplement A).
POM was not statistically different between the two
groups. The adjusted Odds Ratio for study group compared
to the control group was 0.89 (95% confidence interval
(CI) Z 0.43e1.84) (Table 3).
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Table 1 Patient characteristics according to age groups.
Variables Study group N Z 167 Control group N Z 416 p-value
Gender, n (%) 0.192
Female 61 (36.5) 178 (42.8)
Male 106 (63.5) 238 (57.2)
BMI (kg/m2), Mean  SD 21.2  3.7 21.5  3.9 0.387
Insurance type, n (%) <0.001
UCS 77 (46.1) 234 (56.3)
CSMBS 87 (52.1) 148 (35.6)
SSS 2 (1.2) 31 (7.5)
PI/cash 1 (0.6) 3 (0.7)
Smoking status, n (%) 0.038
Non-smokers 34 (20.4) 100 (24.0)
Active smoker or ex-smokers 119 (71.4) 274 (65.9)
Passive smokers 0 14 (3.4)
Unknown 14 (8.4) 28 (6.7)
Pack-year, Median (IQR) 30 (18e47) 20 (10e40) 0.004
Comorbid disease, n (%)
COPD 38 (22.8) 49 (11.8) 0.001
Diabetes mellitus 26 (15.6) 42 (10.1) 0.086
Hypertension 97 (58.1) 129 (31.0) <0.001
Dyslipidemia 45 (27.0) 68 (16.4) 0.005
History of other malignancy 13 (7.8) 23 (5.5) 0.342
Pulmonary function test
Precent predicted FEV1, Mean  SD 82.5  25.0 78.1  21.0 0.199
Preoperative PaO2, Mean  SD 125.5  55.4 124.9  49.5 0.970
Preoperative PaCO2, Mean  SD 43.4  11.0 47.6  31.2 0.562
Preoperative ECG, n (%) <0.001
Normal 94 (56.3) 315 (75.7)
ST-T segment abnormality 24 (14.4) 21 (5.1)
Bundle branch block 10 (6.0) 14 (3.4)
Arrhythmias 9 (5.3) 5 (1.2)
Non-specific abnormality 30 (18.0) 61 (14.7)
Ejection fraction (%), Mean  SD 65.5  9.1 65.5  9.5 0.990
Histology, n (%) 0.072
Adenocarcinoma 102 (61.1) 280 (67.3)
Squamous cell carcinoma 49 (29.3) 83 (20.0)
Large cell carcinoma 5 (3.0) 11 (2.6)
Others 11 (6.6) 42 (10.1)
Tumor staging 0.401
IA1 3 (1.8) 11 (2.6)
IA2 14 (8.4) 33 (7.9)
IA3 22 (13.2) 45 (10.8)
IB 29 (17.4) 45 (10.8)
IIA 10 (6.0) 26 (6.3)
IIB 30 (18.0) 80 (19.2)
IIIA 34 (20.4) 119 (28.6)
IIIB 11 (6.6) 32 (7.7)
IIIC 1 (0.6) 2 (0.5)
IVA 13 (7.8) 23 (5.5)
Cell differentiation, n (%) 0.543
Well differentiation 57 (40.4) 116 (33.5)
Moderately differentiation 52 (36.9) 146 (42.2)
Poorly differentiation 28 (19.9) 73 (21.1)
Undifferentiation 4 (2.8) 11 (3.2)
Intratumoral lymphatic invasion, n (%) 125 (74.9) 297 (71.4) 0.414
Intratumoral vascular invasion, n (%) 64 (38.3) 160 (38.5) 1.000
Visceral pleural invasion, n (%) 27 (16.2) 79 (19.0) 0.477
(continued on next page)
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Tumor recurrence was not statistically significant
different between groups, while long-term cancer-specific
mortality was: patients in the study group had shorter long-
term survival than those in the control group (Fig. 1). In
multivariable analysis, the adjusted hazard ratio (HRadj) for
tumor recurrence in the study group compared to the
Table 1 (continued )
Variables Study group N Z 167 Control group N Z 416 p-value
Perineural invasion, n (%) 13 (3.1) 11 (6.6) 0.066
Tumor necrosis, n (%) 44 (26.4) 123 (29.6) 0.479
BMI Z body mass index, UCS Z Universal coverage scheme, CSMBS Z Civil servant medical benefit scheme, SSS Z Social security
scheme, PIZ Private insurance, COPDZ chronic obstructive pulmonary disease, FEV1Z forced expiratory volume in 1 s, PaO2Z partial
pressure of oxygen in arterial blood, PaCO2 Z partial pressure of carbon dioxide in arterial blood, ECG Z electrocardiogram.
Table 2 Treatment and postoperative outcomes according to age groups.
Variables Study group N Z 167 Control group N Z 416 p-value
Procedures 0.003
Wedge resection 38 (22.8) 58 (14.1)
Segmentectomy 9 (5.4) 7 (1.7)
Lobectomy 118 (70.7) 337 (81.8)
Pneumonectomy 2 (1.2) 10 (2.4)
Approach 0.230
Open thoracotomy 132 (79.0) 345 (83.5)
Video-assisted thoracoscopic surgery 35 (21.0) 68 (16.5)
Mediastinal lymph node evaluation 0.013
Lymph node sampling 31 (22.8) 48 (13.2)
Systematic lymph node dissection 105 (77.2) 315 (86.8)
Lymph node ratio, Median (IQR) 0.20 (0.06e0.48) 0.15 (0.07e0.36) 0.155
Chemotherapy <0.001
No 115 (68.8) 171 (41.1)
Adjuvant therapy 44 (26.4) 208 (50.0)
Neoadjuvant therapy or induction therapy 8 (4.8) 37 (8.9)
Operative time (minutes), Mean  SD 138.6  3.7 148.0  54.5 0.055
Estimated blood loss (mL), Median (IQR) 150 (100e300) 200 (100e300) 0.673
ICU stay (hours), Median (IQR) 35.3 (18.8e70.2) 36.5 (18.1e67.4) 0.741
Immediate extubation after surgery 134 (80.2) 364 (87.5) 0.028
In-hospital mortality 7 (4.2) 4 (1.0) 0.016
Postoperative complications
Pneumonia 5 (3.0) 14 (3.4) 1.000
Re-intubation 3 (1.8) 12 (2.9) 0.572
Atelectasis with bronchoscopy needed 5 (3.0) 9 (2.2) 0.556
Arrhythmias 3 (3.2) 3 (1.0) 0.137
Air leakage 15 (9.0) 31 (7.5) 0.610
Acute renal failure 4 (2.4) 2 (0.5) 0.059
Acute pulmonary embolism 0 1 (0.2) 1.000
Chylothorax 2 (1.2) 4 (1.0) 1.000
Other minor complications 16 (9.6) 30 (7.2) 0.395
Composite major postoperative complications (POM) 20 (12.0) 48 (11.5) 0.887
Length of hospital stay (day), Median (IQR) 7 (6e10) 7 (5e10) 0.205
Long-term cancer-specific mortality 100 (62.5) 229 (55.7) 0.157
Median survival time, month (IQR) 40.98 (28.68e70.38) 56.17 (39.16e88.97) 0.006a
Tumor recurrence, n (%) 70 (41.92) 190 (45.67) 0.839
Median (IQR) 10.98 (5.23e18.77) 11.97 (6.13e23.60) 0.469a
Mean  SD 17.22  17.92 18.86  19.29
Follow-up time (month) 0.006
Median (IQR) 24.0 (9.3e50.4) 34.1 (13.0e61.5)
Mean  SD 33.9  31.0 42.9  36.5
a Analyzed by log-rank test.
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control group was 0.93 (95% CI Z 0.61e1.44, p-
value Z 0.821). Median time to progression in the two
groups was comparable (10.98 months for the study group
and 11.97 months for the control group, Table 2). For long-
term cancer-specific mortality, patients in the study group
were more likely to die (HRadjZ 1.40, 95%CIZ 1.03e1.89,
p-value Z 0.030) than those in the control group; the me-
dian overall survival in the study group was 40.98 months
while in the control group was 56.17 months (p Z 0.006)
(Tables 2 and 4). The 2-year and 5-year survival rate in the
study group and the control group were 58.24% and 36.43%,
and 64.60% and 46.17%, respectively.
In additional analysis, we perform matching (1:1) pro-
pensity score (PS) which was calculated by logistic
regression. The variables included in the model for PS were
gender, insurance status, number of pack year of smoking,
COPD, DM, hypertension, dyslipidemia, preoperative ECG
finding, histology, tumor stage, intratumoral lymphatic
invasion, intratumoral vessel invasion, perineural invasion,
tumor necrosis, surgical approach, surgical procedures,
Table 3 Univariable and multivariable analysis to identify risk factors for composite major complications and in-hospital
mortality (POM).
Variables Univariable analysis Multivariable analysis
OR 95% CI p-value OR 95% CI p-value
Age 70 years vs age <70 years 1.04 0.60e1.82 0.882 0.89 0.43e1.84 0.763
Male vs female 1.52 0.89e2.61 0.125 1.27 0.62e2.61 0.517
BMI (kg/m2) 0.91 0.84e0.98 0.010 0.95 0.86e1.04 0.267
UCS or SSS versus CSMBS or PI 1.22 0.72e2.06 0.451 1.09 0.56e2.12 0.793
Active smoker vs non-smoker 2.31 1.11e4.80 0.006 1.61 0.64e4.03 0.313
Pack-yeara 2.49 1.28e4.83 0.007 e e
COPD 2.79 1.56e4.98 0.001 2.64 1.29e5.41 0.008
Diabetes mellitus 1.01 0.46e2.22 0.978 e e
Hypertension 0.79 0.46e1.34 0.374 e e
Dyslipidemia 0.78 0.40e1.54 0.478 e e
History of other malignancy 0.43 0.11e1.93 0.252 e e
Percent predicted FEV1 0.98 0.96e0.99 0.012 0.98 0.96e1.01 0.153
Preoperative PaO2 0.99 0.98e1.01 0.184 e e
Preoperative PaCO2 1.00 0.98e1.02 0.941 e e
Preoperative ECG, n (%)
Normal 1.00 Reference e e
ST-T segment abnormality 1.57 0.66e3.73 0.309 0.89 0.27e2.95 0.853
Bundle branch block 1.70 0.56e5.21 0.351 1.45 0.39e5.46 0.583
Arrhythmias 1.42 0.31e6.55 0.654 1.32 0.24e7.44 0.751
Non-specific abnormality 1.29 0.65e2.56 0.462 1.04 0.45e2.38 0.926
Ejection fraction (%), Mean  SD 0.99 0.93e1.06 0.785 e e
Histology
Adenocarcinoma 1.00 Reference 1.00 Reference
Squamous cell carcinoma 2.20 1.26e3.87 0.006 1.51 0.75e3.06 0.247
Large cell carcinoma 3.30 1.01e10.80 0.048 1.77 0.41e4.61 0.440
Others 1.03 0.38e2.76 0.949 0.82 0.25e2.69 0.745
Tumor staging (8th IASLC edition)
Stage I 1.00 Reference 1.00 Reference
Stage II 1.43 0.71e2.91 0.319 1.12 0.57e2.83 0.788
Stage III 1.93 1.03e3.63 0.041 1.28 0.65e2.96 0.527
Stage IV 1.36 0.43e4.30 0.601 1.65 0.33e5.69 0.518
Surgical Procedure
Lobectomy 1.00 Reference 1.00 Reference
Sublobar resection 0.64 0.30e1.33 0.228 1.03 0.31e3.43 0.960
Pneumonectomy 3.64 1.06e22.75 0.040 2.97 0.59e14.78 0.183
VATS vs Open thoracotomy 0.50 0.22e1.12 0.092 0.59 0.16e2.15 0.429
SLNS vs SLND 1.30 0.66e2.56 0.418 0.83 0.36e1.90 0.661
Neoadjuvant therapy or induction therapy 1.18 0.48e2.90 0.717 1.30 0.47e3.59 0.617
Operative time (minutes) 1.01 1.01e1.02 0.002 1.00 0.99e1.01 0.652
Estimated blood loss (mL) 1.01 1.01e1.02 <0.001 1.00 0.99e1.01 0.732
BMI Z Body mass index, UCS Z Universal coverage scheme, CSMBS Z Civil servant medical benefit scheme, SSS Z Social security
scheme, PI Z Private insurance, COPD Z chronic obstructive pulmonary disease, FEV1 Z Force expiratory volume in 1 min,
SLND Z Systematic lymph node dissection, SLNS Z Systematic lymph node sampling, OR Z Odd ratio, CI Z Confidence interval.
a Not include in multivariable analysis due to multicollinearity with smoking status.
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Figure 1 KaplaneMeier curve demonstrated recurrent-free survival (A) and overall survival (B) probability between elderly and non-elderly group (p Z 0.469 and p Z 0.006,
respectively, analyzed by log-rank test.
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type of lymph node dissection, and chemotherapy. After
matching, 153 patients were included in both groups.
There were no statistically significant differences in term
of patient characteristics, pulmonary function test, histo-
logic findings, tumor staging, pathologic findings, surgical
procedures, surgical approaches, lymphatic dissection,
and induction chemotherapy between the two groups.
Hypertension was significant higher in the study group
(Appendix B). There were 6 patients died after surgery in
the study group; caused by multiple postoperative
complications such as pneumonia, septicemia, or acute
respiratory distress syndrome. ICU stay was significantly
longer in the study group. Long-term cancer-specific mor-
tality was significant higher in the study group (Appendix
C). In multivariable analysis, there were no significant
difference in term of ICU stay, composite major post-
operative complications, and tumor recurrence between
the two groups. However, patients in the study group were
more likely to die (long-term cancer-specific mortality)
than the control group (Appendix D). In summary, the
Table 4 Univariable and multivariable analysis to identify prognostic factors of long-term cancer-specific mortality.
Variables Univariable analysis Multivariable analysis
HR 95% CI p-value HR 95% CI p-value
Age 70 years vs Age <70 years 1.35 1.07e1.70 0.010 1.40 1.03e1.89 0.030
Male vs female 1.61 1.29e2.01 <0.001 1.22 0.91e1.63 0.181
UCS or SSS versus CSMBS or PI 1.43 1.15e1.79 0.001 1.82 1.37e2.42 <0.001
Active smoker vs non-smoker 1.67 1.27e2.20 <0.001 1.20 0.86e1.67 0.303
Pack-yeara 1.01 1.01e1.02 0.011 e e
COPD 1.37 1.03e1.81 0.028 1.46 1.03e2.07 0.038
Diabetic mellitus 1.16 0.84e1.60 0.378 e e
Hypertension 0.84 0.67e1.05 0.126 e e
Dyslipidemia 0.84 0.63e1.12 0.229 e e
History of other malignancy 0.54 0.32e0.93 0.025 e e
Histology
Adenocarcinoma 1.00 Reference 1.00 Reference
Squamous cell carcinoma 1.02 0.79e1.32 0.881 0.67 0.48e0.94 0.020
Large cell carcinoma 2.22 1.24e3.97 0.007 1.29 0.49e3.37 0.658
Others 1.10 0.76e1.59 0.607 0.85 0.37e1.94 0.851
Cell differentiation
Well differentiation 1.00 Reference 1.00 Reference
Moderately differentiation 1.19 0.91e1.56 0.204 1.06 0.76e1.48 0.769
Poorly differentiation 1.57 1.15e2.13 0.004 1.29 0.89e1.50 0.162
Undifferentiation 1.88 1.03e3.43 0.040 2.52 0.89e7.17 0.084
Intratumoral lymphatic invasion 1.58 1.21e2.05 0.001 1.56 1.02e2.39 0.031
Intratumoral vascular invasion 1.54 1.24e1.91 <0.001 1.13 0.85e1.50 0.282
Visceral pleural invasion 1.23 1.08e1.41 0.003 1.58 1.14e2.19 0.007
Perineural invasion 1.29 0.76e2.20 0.351 e e
Tumor necrosis 1.44 1.15e1.80 0.002 1.20 0.89e1.63 0.227
Tumor staging (8th IASLC edition)
Stage I 1.00 Reference 1.00 Reference
Stage II 1.55 1.15e2.10 0.005 1.84 1.25e2.70 0.002
Stage III 2.30 1.75e3.03 <0.001 2.48 1.67e3.67 <0.001
Surgical Procedure
Lobectomy 1.00 Reference 1.00 Reference
Sublobar resection 1.02 0.77e1.36 0.879 1.02 0.61e1.68 0.849
Pneumonectomy 2.47 1.26e4.85 0.006 2.62 1.07e6.37 0.028
VATS vs Open thoracotomy 0.86 0.63e1.19 0.367 e e
SLNS vs SLND 1.52 1.13e2.05 0.006 1.37 0.91e2.07 0.160
Lymph node ratio 2.94 1.87e4.64 <0.001 1.48 0.80e2.72 0.190
Chemotherapyb
No 1.00 Reference 1.00 Reference
Adjuvant therapy 0.73 0.57e0.95 0.019 0.52 0.38e0.71 <0.001
Neoadjuvant therapy or induction therapy 0.94 0.55e1.62 0.740 0.68 0.38e1.19 0.136
UCS Z Universal coverage scheme, CSMBS Z Civil servant medical benefit scheme, SSS Z Social security scheme, PI Z Private in-
surance, COPD Z Chronic obstructive pulmonary disease, SLND Z Systematic lymph node dissection, SLNS Z Systematic lymph node
sampling, HR Z Hazard ratio, CI Z Confidence interval.
a Not include in multivariable analysis due to multicollinearity with smoking status.
b Stage I patients were not included in this analysis.
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results from matching propensity score analysis were not
different from regression analysis in both short-term and
long-term outcomes.
In subgroup analysis in patients age 70 years, adverse
prognostic factors for long-term cancer specific mortality
were having universal coverage scheme, presence of
intratumoral lymphatic invasion, presence of perineural
invasion, undergoing pneumonectomy (compared to lo-
bectomy), not undergo systematic lymph node dissection,
not receiving adjuvant chemotherapy (in stage II and III
disease after surgery) and higher stage of disease (Table 5).
4. Discussion
Pulmonary resection with or without mediastinal lymph node
sampling or dissection is commonly accepted as the standard
treatment of choice for early or local NSCLC patients;
Table 5 Univariable and multivariable analysis to identify prognostic factors of long-term cancer-specific mortality in patients
age more than 70 years (N Z 167).
Variables Univariable analysis Multivariable analysis
HR 95% CI p-value HR 95% CI p-value
Male vs female 1.42 0.95e2.12 0.092 1.01 0.57e1.79 0.985
UCS versus CSMBS 1.33 0.91e1.94 0.141 1.70 1.03e2.79 0.037
Active smoker vs non-smoker 1.73 1.01e2.96 0.046 1.38 0.66e2.86 0.394
Pack-yeara 1.01 0.99e1.01 0.147 e e
COPD 1.10 0.71e1.72 0.674 e e
Diabetic mellitus 1.25 0.76e2.05 0.387 e e
Hypertension 0.62 0.42e0.90 0.013 0.60 0.35e1.01 0.054
Dyslipidemia 0.64 0.40e1.02 0.061 1.14 0.59e2.19 0.700
History of other malignancy 0.43 0.17e1.06 0.066 0.69 0.22e2.12 0.515
Histology
Adenocarcinoma 1.00 Reference 1.00 Reference
Squamous cell carcinoma 1.15 0.75e1.76 0.523 0.75 0.44e1.30 0.308
Large cell carcinoma 1.62 0.59e4.47 0.351 1.57 0.51e4.84 0.434
Others 1.81 0.92e3.55 0.084 1.88 0.75e4.71 0.178
Cell differentiation
Well differentiation 1.00 Reference e e e
Moderately differentiation 0.88 0.54e1.42 0.598 e e e
Poorly differentiation 1.60 0.95e2.70 0.078 e e e
Undifferentiation 0.97 0.30e3.14 0.954 e e e
Intratumoral lymphatic invasion 1.88 1.13e3.13 0.015 2.83 1.28e6.29 0.010
Intratumoral vascular invasion 1.47 1.01e2.15 0.050 1.20 0.70e2.05 0.516
Visceral pleural invasion 1.35 0.81e1.05 0.067 0.84 0.60e1.18 0.313
Perineural invasion 2.22 1.07e4.61 0.032 2.80 1.13e6.94 0.026
Tumor necrosis 1.28 0.84e1.96 0.248 e e e
Tumor staging (8th IASLC edition)
Stage I 1.00 Reference 1.00 Reference
Stage II 1.42 0.87e2.31 0.161 1.13 0.61e2.09 0.692
Stage III 1.53 0.94e2.49 0.086 2.02 1.06e3.85 0.033
Stage IV 2.55 1.32e4.93 0.005 3.40 1.29e8.94 0.013
Procedures
Lobectomy 1.00 Reference 1.00 Reference
Sublobar resection 0.81 0.52e1.27 0.357 1.08 0.54e2.14 0.847
Pneumonectomy 14.29 3.15e64.87 0.001 72.58 5.34e986.21 0.001
VATS vs Open thoracotomy 0.85 0.50e1.43 0.534 e e
SLNS vs SLND 1.96 1.22e3.15 0.005 2.23 1.16e4.30 0.017
Lymph node ratio 2.64 1.21e5.74 0.014 1.30 0.49e3.48 0.598
Chemotherapyb
No chemotherapy 1.00 Reference 1.00 Reference
Adjuvant therapy 0.71 0.43e1.17 0.179 0.51 0.29e0.89 0.013
Neoadjuvant therapy or induction therapy 0.82 0.30e2.29 0.709 0.52 0.17e1.54 0.227
UCS Z Universal Coverage Scheme, CSMBS Z the Civil Servant Medical Benefit Scheme, SSS Z Social security scheme, PI Z Private
insurance, COPD Z chronic obstructive pulmonary disease, SLNDZ Systematic lymph node dissection, SLNSZ Systematic lymph node
sampling, HR Z Hazard ratio, CI Z Confidence interval.
a Not include in multivariable analysis due to multicollinearity with smoking status.
b Stage I patients were not included in data analysis.
162 A. Tantraworasin et al.
however, previous studies demonstrated that surgery rate in
elderly patients is lower than in younger ages (4.9% versus
17.7%).4 This may be due to a combination of poor medical
and physiological status in elderly patients, which could be
responsible for the higher postoperative morbidity and
mortality.22 Moreover, impairment of immune response in
elderly patients may lead to postoperative complications
such as respiratory tract infections.23
The present study found that some clinical characteris-
tics were different between patient age 70 years and age
<70 years such as the incidence of COPD, hypertension,
dyslipidemia, abnormal ECG, and number of pack-years of
smoking. This difference may explain by age-related dif-
ference occurs in the general population,24 not only in the
analyzed groups operated for NSCLC. For postoperative
outcomes in NSCLC patients between the study group and
the control group patients, shows no statistically significant
differences in term of POM between the two groups.
Therefore, patients age 70 years seem to have no
increased risk of postoperative complications compared to
patients age <70 years, except for the incidence of post-
operative acute renal failure. This difference may be
explained by the decline in glomerular filtrate rate in
elderly patients.25 The incidence of in-hospital mortality in
our cohort was 1.9% (11 in 583): 4.2% for study group and
1.0% for control group, which was comparable to the result
of a recent study by Detillon et al.26 The operative mor-
tality in their cohort was 2.1%: 2.6% for patients aged
70e79 years and 1.0% for patients aged 60e69 years.
Similar to our study, they also found that there was no
statistically significant difference in the incidence of post-
operative complications between the two groups. Ogawa
et al27 reported that lung cancer elderly patients (cut-off
age of 75 years) were not at a significant higher risk for
postoperative complications (OR Z 1.13, 95%
CIZ 0.70e1.83). On the contrary, Liu et al4 found that the
postoperative hospital stay, comorbidities and mortality
rates, and length in intensive care unit in elderly patients
were significantly greater than in non-elderly patients.
Unfortunately, this publication only present univariable
analyses without any multivariable analysis results. In
matching propensity score analysis of this study, ICU stay
and in-hospital mortality in the study group were signifi-
cantly greater than in the control group. However, there
was no statistically significant differences in term of POM
between the two groups, like showed in the regression
method.
We found that sublobar resection was more frequent
performed in study group with stage I disease, especially in
stage IA3, however, in other stages, the proportion of pa-
tients who underwent sublobar and lobar resection was not
statistically different between the two groups. The multi-
variable analysis showed that there was no significant dif-
ference in POM. This suggests that lobectomy is safe even in
patients older than 70 years. Previous studies stated that
sublobar resection might achieve similar long-term survival
compared to lobectomy in elderly patients, especially
those with low %FEV1 and tumor less than 2 cm.28e31
However, Zhang et al stated that elder age alone could
not be used to select patients for sublobar resection in
early stage NSCLC because older patients tend to have
worse overall survival and lung cancer-specific survival.32
Recently, Yang et al33 have developed a prospective ran-
domized controlled multicenter non-inferiority trial to
compare disease-free survival, peri-operative complica-
tions and mortality and overall survival between sublobar
resection and lobectomy. The trial is still ongoing.
COPD was one of the risk factors included in the major
complications and in-hospital mortality in the present
study, similar to the study by Detillon et al.26 However
other studies26,27 found that other factors associated with
operative morbidities and mortality are gender, being a
smoker, FEV1% or DLCO % per 10% decrease, coronary artery
bypass graft, congestive heart failure, high ECOG score
(eastern cooperative oncology group) and resection more
extensive than limited. We found that smoking status, %
predicted FEV1, and pneumonectomy were significant risk
factors for composite postoperative complications and in-
hospital mortality at the univariable analysis only. We
attribute the results of previous studies to the small sample
size causing lower statistical power.
There was no statistically significant difference in tumor
recurrence between the two groups both in the univariable
and multivariable analysis. However, this result is not
conclusive because the median follow-up time in the study
group was significantly shorter than in the control group (24
versus 34.1 months); therefore, a longer follow-up time is
needed.
Patients in the study group were more likely to experi-
ence long-term cancer-specific mortality than those in the
control group, similarly to what reported by previous
studies.27,34 In study group, we found 7 adverse prognostic
factors associated with long-term cancer-specific mortal-
ity: universal coverage scheme, presence of intratumoral
lymphatic invasion, perineural invasion, undergoing pneu-
monectomy (compared with lobectomy), undergoing sys-
tematic lymph node sampling (compared with systematic
lymph node dissection), not receiving adjuvant chemo-
therapy (in stage II and III disease after surgery) and higher
stage of disease. In Thailand, targeted therapy (Epidermal
growth factor receptor-Tyrosine kinase inhibitor) been
approved for use as first-line therapy but patients must pay
out of pocket. For second-line or third-line therapy, the
reimbursement has been approved since 2012 but limited to
the Civil Servant Medical Benefits Scheme under restricted
criteria. The reimbursement did not cover in the universal
coverage scheme or social security scheme. This may be the
reason for shorter survival in patients with universal
coverage scheme or social security insurance scheme.
Intratumoral lymphatic invasion and perineural invasion
were reported as adverse prognostic factors for long-term
cancer-specific mortality in previous studies,35e37 howev-
er, these factors were not studied as we did in the present
study. Although patients in the study group undergoing
pneumonectomy showed worse long-term survival than
those undergoing lobectomy, the outcomes in the study
group were similar to the control group in terms of POM.
This suggests that patients should not be denied pneumo-
nectomy based on age alone. Very careful selection of
elderly patients is essential in order to optimize survival
and quality of life, as reported by previous studies.38,39
Because there were only 2 patients (1.87%) in the study
group who underwent pneumonectomy and both of them
died, the adjusted hazard ratio was overestimated with
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very wide 95% confidence interval. Therefore, the associ-
ation between pneumonectomy and overall survival could
not be assessed in this study. However, pneumonectomy
would have poorer survival because tumor stage was more
advance and quality of life was certainly worse.40
Previous studies demonstrated that systematic lymph
node dissection (radical dissection) in patients age  70
years resulted in increased postoperative pulmonary com-
plications, shorter survival, and increase overall mortal-
ity.41,42 However, our study found that systematic lymph
node dissection was associated with longer survival in
comparison to lymph node sampling in study group. Further
studies are needed to clarify this aspect. VATS approach is
acceptable for non-elderly NSCLC patients; however, in
elderly patients it is still controversial. Recent studies
demonstrated that VATS approach was less invasive, had
lower postoperative morbidity, shorter length of hospital
stay than open thoracotomy,43 however some studies
stated that this approach is associated with higher post-
operative complication rates.44 Our result showed that
VATS approach was associated with longer survival but not
in a statistically significant manner, similar to previous
studies.45 Previous studies demonstrated that stage of dis-
ease was not significantly associated with overall survival in
elderly patients, and that half of the elderly NSCLC patients
(especially octogenarians) died of non-cancer related dis-
ease.45,46 However, our result showed that stage of disease
was associated with long-term cancer-specific mortality in
the multivariable analysis model. Although this study did
not add anything new in the fields of lung cancer or VATS,
the result of this study ensures that surgery in selected
older patients is safe and the results comparable to what
observed in younger patients. Furthermore, we can reas-
sure or convince our patients who have indication or fit for
adjuvant therapy which still have benefits on long-term
survival in patients age >70 years, especially in patients
who have adverse prognostic factors. Some patients and
their relatives believe that they cannot tolerate the side
effects of the drug because of old age.
This study has some limitations: it is retrospective in
nature and single center. There are some selection biases
for surgical procedures in elderly patients. Although there
was no difference of pulmonary function between the two
groups, sublobar resection was more likely to undergo in
patients age 70 years. The reason may from other unre-
corded comorbid diseases that may influence the decision
of surgical procedures. However, this single-center data set
is built in a systematic way with a good data recording
system, therefore, the missing data in each variable of this
study is less than 5%, except for pulmonary function test
(15% of missing data). In addition, we used multiple impu-
tations to address missing data, and presented multivari-
able analyses to analyze the data in a more comprehensive
way in comparison to previous papers on this topic.4
5. Conclusion
Postoperative morbidity and in-hospital mortality for pul-
monary resection in NSCLC patients age 70 years were
acceptable and comparable to what observed in patients
age <70 years. Disease-free survival was not different
between groups, however, patients age 70 years had
shorter long-term survival than patients age <70 years. In
the subgroup of patients age 70 years, there were 7
adverse prognostic factors for long-term cancer-specific
mortality; UCS coverage, presence of intratumoral
lymphatic invasion, perineural invasion, higher stage of
disease, underwent pneumonectomy, underwent system-
atic lymph node sampling, and not receiving adjuvant
chemotherapy. Therefore, systematic lymph node dissec-
tion should be performed rather than lymph node sampling.
Patients age 70 years presenting with intratumoral
lymphatic invasion or perineural invasion should be further
considered for possible adjuvant chemotherapy. Effect of
insurance coverage on lung cancer survival should be
explored in future studies. Further studies with larger
sample size are warranted.
Conflict of interest
The authors have no conflicts of interest to declare.
Acknowledgements
This work was supported by Faculty of Medicine Research
Fund, Chiang Mai University (Grant number 070/2559),
Chiang Mai, Thailand.
Appendix A. Supplementary data
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.asjsur.2019.03.006.
References
1. Gridelli C, Maione P, Colantuoni G, et al. Chemotherapy of non-
small cell lung cancer in elderly patients. Curr Med Chem.
2002;9(16):1487e1495.
2. Pei G, Zhou S, Han Y, et al. Risk factors for postoperative
complications after lung resection for non-small cell lung
cancer in elderly patients at a single institution in China. J
Thorac Dis. 2014;6(9):1230e1238.
3. Shiono S, Abiko M, Sato T. Postoperative complications in
elderly patients after lung cancer surgery. Interact Cardiovasc
Thorac Surg. 2013;16(6):819e823.
4. Liu HC, Huang WC, Wu CL, et al. Surgery for elderly lung
cancer. Ann Thorac Cardiovasc Surg. 2013;19(6):416e422.
5. Srisomboon C, Koizumi K, Haraguchi S, et al. Thoracoscopic
surgery for non-small-cell lung cancer: elderly vs. octogenar-
ians. Asian Cardiovasc Thorac Ann. 2013;21(1):56e60.
6. Nakagawa T, Negoro Y, Matsuoka T, et al. Comparison of the
outcomes of stereotactic body radiotherapy and surgery in
elderly patients with cT1-2N0M0 non-small cell lung cancer.
Respir Invest. 2014;52(4):221e226.
7. Rusthoven CG, Kavanagh BD, Karam SD. Improved survival with
stereotactic ablative radiotherapy (SABR) over lobectomy for
early stage non-small cell lung cancer (NSCLC): addressing the
fallout of disruptive randomized data. Ann Transl Med. 2015;
3(11):149.
8. Davis JN, Medbery 3rd C, Sharma S, et al. Stereotactic body
radiotherapy for early-stage non-small cell lung cancer: clin-
ical outcomes from a National Patient Registry. J Radiat Oncol.
2015;4(1):55e63.
164 A. Tantraworasin et al.
9. Baldvinsson K, Oskarsdottir GN, Orrason AW, et al. Resection
rate and operability of elderly patients with non-small cell lung
cancer: Nationwide study from 1991 to 2014. Interact Car-
diovasc Thorac Surg. 2017;24(5):733e739.
10. Bolukbas S, Beqiri S, Bergmann T, et al. Pulmonary resection of
non-small cell lung cancer: is survival in the elderly not
affected by tumor stage after complete resection? Thorac
Cardiovasc Surg. 2008;56(8):476e481.
11. Park B, Lee G, Kim HK, et al. A retrospective comparative
analysis of elderly and younger patients undergoing pulmonary
resection for stage I non-small cell lung cancer. World J Surg
Oncol. 2016;14(1):13.
12. Cerfolio RJ, Bryant AS. Survival and outcomes of pulmonary
resection for non-small cell lung cancer in the elderly: a nested
case-control study. Ann Thorac Surg. 2006;82(2):424e429.
discussion 9-30.
13. Owonikoko TK, Ragin CC, Belani CP, et al. Lung cancer in elderly
patients: an analysis of the surveillance, epidemiology, and end
results database. J Clin Oncol. 2007;25(35):5570e5577.
14. Burfeind Jr WR, Tong BC, O’Branski E, et al. Quality of life
outcomes are equivalent after lobectomy in the elderly. J
Thorac Cardiovasc Surg. 2008;136(3):597e604.
15. Schulte T, Schniewind B, Walter J, et al. Age-related impair-
ment of quality of life after lung resection for non-small cell
lung cancer. Lung Cancer. 2010;68(1):115e120.
16. SoTS. http://sts.org/sections/stsnationaldatabae_2010; 2010.
17. Howington JA, Blum MG, Chang AC, et al. Treatment of stage I
and II non-small cell lung cancer: diagnosis and management of
lung cancer, 3rd ed: American College of Chest Physicians
evidence-based clinical practice guidelines. Chest. 2013;143(5
Suppl):e278See313S.
18. Lardinois D, De Leyn P, Van Schil P, et al. ESTS guidelines for
intraoperative lymph node staging in non-small cell lung can-
cer. Eur J Cardiothorac Surg. 2006;30(5):787e792.
19. Naruke T, Suemasu K, Ishikawa S. Lymph node mapping and
curability at various levels of metastasis in resected lung
cancer. J Thorac Cardiovasc Surg. 1978;76(6):832e839.
20. Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung
cancer staging project: proposals for revision of the TNM stage
groupings in the forthcoming (eighth) edition of the TNM
classification for lung cancer. J Thorac Oncol. 2016;11(1):
39e51.
21. Rubin DB, Schenker N. Multiple imputation in health-care da-
tabases: an overview and some applications. Stat Med. 1991;
10(4):585e598.
22. Balduyck B, Hendriks J, Lauwers P, et al. Quality of life evo-
lution after lung cancer surgery in septuagenarians: a pro-
spective study. Eur J Cardiothorac Surg. 2009;35(6):
1070e1075. discussion 5.
23. Meyer KC. Lung infections and aging. Ageing Res Rev. 2004;
3(1):55e67.
24. Santoni G, Angleman S, Welmer AK, et al. Correction: age-
related variation in health status after age 60. PLoS One.
2015;10(6), e0130024.
25. Venuta F, Diso D, Onorati I, et al. Lung cancer in elderly pa-
tients. J Thorac Dis. 2016;8(Suppl 11):S908eS914.
26. Detillon D, Veen EJ. Postoperative outcome after pulmonary
surgery for non-small cell lung cancer in elderly patients. Ann
Thorac Surg. 2018;105(1):287e293.
27. Ogawa F, Wang G, Matsui Y, et al. Risk factors for postoperative
complications in the elderly with lung cancer. Asian Cardiovasc
Thorac Ann. 2013;21(3):313e318.
28. Qiu C, Wang G, Xu J, et al. Sublobectomy versus lobectomy for
stage I non-small cell lung cancer in the elderly. Int J Surg.
2017;37:1e7.
29. Razi SS, John MM, Sainathan S, et al. Sublobar resection is
equivalent to lobectomy for T1a non-small cell lung cancer in
the elderly: a surveillance, epidemiology, and end results
database analysis. J Surg Res. 2016;200(2):683e689.
30. Fiorelli A, Caronia FP, Daddi N, et al. Sublobar resection versus
lobectomy for stage I non-small cell lung cancer: an appro-
priate choice in elderly patients? Surg Today. 2016;46(12):
1370e1382.
31. Liu T, Liu H, Li Y. Early lung cancer in the elderly: sublobar
resection provides equivalent long-term survival in comparison
with lobectomy. Contemp Oncol (Pozn). 2014;18(2):111e115.
32. Zhang Y, Yuan C, Zhang Y, et al. Survival following segmen-
tectomy or lobectomy in elderly patients with early-stage lung
cancer. Oncotarget. 2016;7(14):19081e19086.
33. Yang F, Sui X, Chen X, et al. Sublobar resection versus lobec-
tomy in Surgical Treatment of Elderly Patients with early-stage
non-small cell lung cancer (STEPS): study protocol for a ran-
domized controlled trial. Trials. 2016;17:191.
34. Onaitis MW, Furnary AP, Kosinski AS, et al. Prediction of long-
term survival after lung cancer surgery for elderly patients in
the society of thoracic Surgeons general thoracic surgery
database. Ann Thorac Surg. 2018;105(1):309e316.
35. Ma KF, Chu XY, Liu Y. Clinical significance of lymphatic vessel
invasion in stage I non-small cell lung cancer patients. Genet
Mol Res. 2015;14(1):1819e1827.
36. Nentwich MF, Bohn BA, Uzunoglu FG, et al. Lymphatic invasion
predicts survival in patients with early node-negative non-
small cell lung cancer. J Thorac Cardiovasc Surg. 2013;146(4):
781e787.
37. Kilicgun A, Turna A, Sayar A, et al. Very important histopath-
ological factors in patients with resected non-small cell lung
cancer: necrosis and perineural invasion. Thorac Cardiovasc
Surg. 2010;58(2):93e97.
38. Kim TH, Park B, Cho JH, et al. Pneumonectomy for clinical
stage I non-small cell lung cancer in elderly patients over 70
Years of age. Kor J Thorac Cardiovasc Surg. 2015;48(4):
252e257.
39. Speicher PJ, Ganapathi AM, Englum BR, et al. Survival in the
elderly after pneumonectomy for early-stage non-small cell
lung cancer: a comparison with nonoperative management. J
Am Coll Surg. 2014;218(3):439e449.
40. Leo F, Scanagatta P, Vannucci F, et al. Impaired quality of life
after pneumonectomy: who is at risk? J Thorac Cardiovasc
Surg. 2010;139(1):49e52.
41. Okami J, Higashiyama M, Asamura H, et al. Pulmonary resec-
tion in patients aged 80 years or over with clinical stage I non-
small cell lung cancer: prognostic factors for overall survival
and risk factors for postoperative complications. J Thorac
Oncol. 2009;4(10):1247e1253.
42. Chida M, Minowa M, Karube Y, et al. Worsened long-term
outcomes and postoperative complications in octogenarians
with lung cancer following mediastinal lymph-node dissection.
Interact Cardiovasc Thorac Surg. 2009;8(1):89e92.
43. Saha SP, Bender M, Ferraris VA, et al. Surgical treatment of
lung cancer in octogenarians. South Med J. 2013;106(6):
356e361.
44. Sui X, Zhao H, Wang J, et al. Outcome of VATS lobectomy for
elderly non-small cell lung cancer: a propensity score-matched
study. Ann Thorac Cardiovasc Surg. 2015;21(6):529e535.
45. Hino H, Murakawa T, Ichinose J, et al. Results of lung cancer
surgery for octogenarians. Ann Thorac Cardiovasc Surg. 2015;
21(3):209e216.
46. Fanucchi O, Ambrogi MC, Dini P, et al. Surgical treatment of
non-small cell lung cancer in octogenarians. Interact Car-
diovasc Thorac Surg. 2011;12(5):749e753.
Pulmonary resection in elderly lung cancer 165
